Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth Is Accelerating As Industry Transformation Continues
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Anti-Vascular Endothelial Growth Factor Therapeutics Market Size, Value And Growth Trends Through 2030
The market for anti-vascular endothelial growth factor therapeutics has experienced slight expansion over the recent period. Forecasts indicate an increase from $12.17 billion in 2025 to $12.36 billion in 2026, reflecting a compound annual growth rate (CAGR) of 1.6%. This historical growth has been driven by factors such as the regulatory approval of treatments like Lucentis and Eylea, a higher frequency of age-related macular degeneration cases, an uptick in diabetic retinopathy occurrences, progress in molecular biology aimed at blocking angiogenesis, and the broader availability of ophthalmology services within hospital settings.
The market for anti-vascular endothelial growth factor therapeutics is projected to experience consistent expansion over the coming years. By 2030, it is anticipated to reach a value of $13.59 billion, reflecting a compound annual growth rate (CAGR) of 2.4%. This projected growth during the forecast period is largely driven by the introduction of next-generation anti-VEGF treatments, heightened investment in precision oncology, increasing penetration of biosimilars into the market, rising healthcare spending across emerging economies, and the broader adoption of combination therapies for retinal conditions. Key trends shaping the forecast period include the growing use of anti-VEGF therapies within ophthalmology, the expansion of targeted approaches to cancer treatment, the development of biosimilar anti-VEGF medications, an increasing elderly population fueling demand for age-related macular degeneration (AMD) therapies, and the widening availability of outpatient and ambulatory care centers.
Download A Free Sample Report For Comprehensive Market Insights:
Anti-Vascular Endothelial Growth Factor Therapeutics Market Expansion Drivers: What Is Shaping Future Growth?
The rising occurrence of eye-related disorders is anticipated to boost the expansion of the anti-vascular endothelial growth factor therapeutics market in the coming period. The prevalence of ophthalmic diseases is defined as the count or percentage of people within a specific population who have been identified with or show signs of particular eye conditions. Anti-vascular endothelial growth factor (VEGF) therapeutics contribute to lowering the prevalence of these diseases by successfully managing conditions like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As an example, in August 2023, the World Health Organization, a public health body based in Switzerland, reported that approximately 2.2 billion individuals globally have near or distance vision impairment, with 1 billion people affected by such impairment. Among these cases, 88.4 million involve refractive errors, 94 million have cataracts, 8 million are affected by age-related macular degeneration, and around 3.9 million suffer from diabetic retinopathy. Consequently, the growing prevalence of ophthalmic diseases is fueling the growth of the anti-vascular endothelial growth factor therapeutics market.
Anti-Vascular Endothelial Growth Factor Therapeutics Market Segment Performance And Strategic Opportunities
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Anti-Vascular Endothelial Growth Factor Therapeutics Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Strategic collaborations among top firms in the anti-VEGF therapeutics space are becoming increasingly common, aimed at speeding up the development, marketing, and uptake of VEGF inhibitors. These alliances help participants tap into complementary strengths, gain access to advanced technologies, and increase their footprint in the market. For example, in January 2025, Teva Pharmaceuticals International GmbH—a Swiss subsidiary of Teva Pharmaceutical Industries focused on biosimilars and complex generics—formed a strategic agreement with Klinge Biopharma GmbH and Formycon AG to market FYB203, a biosimilar candidate for Eylea (aflibercept), across Europe (excluding Italy) and Israel. Through this arrangement, Teva uses its well-established sales and distribution channels to bolster its role in the anti-VEGF therapeutics sector. Formycon AG is tasked with developing FYB203, while Klinge Biopharma GmbH retains sole global commercialization rights for the product.
Anti-Vascular Endothelial Growth Factor Therapeutics Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market are F. Hoffmann-La Roche AG, Pfizer Inc., Coherus BioSciences Inc., Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Allergan Inc., Novartis AG, Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited
Access The Complete Anti-Vascular Endothelial Growth Factor Therapeutics Market Report:
Anti-Vascular Endothelial Growth Factor Therapeutics Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2025. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
